METHOD FOR PREVENTION AND TREATMENT OF ALLERGIC RHINITIS BEFORE AND AFTER ENDOSCOPIC ADENOTOMY IN CHILDREN Russian patent published in 2022 - IPC A61P11/02 A61K31/47 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to pediatric otorhinolaryngology, allergology, clinical pharmacology, and is intended for pediatricians, otorhinolaryngologists, allergists, clinical pharmacologists, family physicians for the prevention and treatment of allergic rhinitis in the pre- and postoperative period in children with pharyngeal hypertrophy tonsils. In children aged 3 to 5 years with hypertrophy of the pharyngeal tonsil, who are indicated for endoscopic adenotomy, a complete blood count is performed; after which the allergization index (AI) is calculated according to the formula. With IA values less than 2.18, prevention and treatment of allergic rhinitis is not required before and after endoscopic adenotomy. At IA values of 2.18 and above, an allergen is searched for, followed by its elimination for three months before and after endoscopic adenotomy with systemic use of the leukotriene receptor blocker - Montelukast once at night 4 mg per day for 1 month after endoscopic adenotomy.

EFFECT: invention provides a simple, effective, inexpensive diagnostic criterion and recommendations for the prevention and treatment of allergic rhinitis before and after endoscopic adenotomy in children.

1 cl, 3 ex